KIT and gastrointestinal stromal tumor: Imatinib alone was unable to completely turn-off MAPK signaling in GIST-T1, and PI3K/MAPK signaling in resistant cell lines, suggesting that residual signaling can facilitate survival of GIST cells in the presence of KIT inhibitors.